We have located links that may give you full text access.
Circular RNA circ-RAD23B promotes cell growth and invasion by miR-593-3p/CCND2 and miR-653-5p/TIAM1 pathways in non-small cell lung cancer.
Biochemical and Biophysical Research Communications 2019 March 13
Non-small cell lung cancer (NSCLC) is an aggressive malignancy with poor clinical outcomes. Accumulating evidence indicated that dysregulation of circular RNAs (circRNAs) plays a key role in multiple solid tumors. In this study, circ-RAD23B was explored. The expression of circ-RAD23B in NSCLC was detected by RT-qPCR. The clinical value of circ-RAD23B was analyzed by Fisher's exact test and Kaplan-Meier curves. Gain and loss of function experiments were carried out to elucidate the biological functions of circ-RAD23B in NSCLC cell lines. Dual luciferase reporter assay and rescue experiments were used to reveal the mechanism of circ-RAD23B. The findings demonstrated that circ-RAD23B, identified to be amplified and overexpressed in NSCLC, was associated with lymph node invasion, lower differentiation grade and shorter overall survival (OS). Furthermore, circ-RAD23B functions as an oncogene in NSCLC cells. Mechanistically, circ-RAD23B could sponge miR-593-3p and miR-653-5p and thus elevate CCND2 and TIAM1 expression, respectively. Rescue assays proved that circ-RAD23B promotes cell growth via miR-593-3p/CCND2 axis and facilitates cell invasion by miR-653-5p/TIAM1 pathway. Taken together, we propose circ-RAD23B as a promising biomarker and therapeutic target for NSCLC.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app